Priority Populations Working Groups
The purpose of the Priority Population Working Groups is to provide leadership and advice for the OHTN Cohort Study by:
- Identifying priority research questions;
- Participating in the collaborative development of OHTN Cohort Study’s Concept Sheets, Data Requests, and applications for external funding to support OHTN Cohort Study analysis projects and sub-studies;
- To review and provide constructive feedback on OHTN Cohort Study’s Concept Sheets when required;
- Collaborate with other priority population work groups when required;
- Review, interpret, and produce ad hoc data and analysis to support policy and programs
- Advise on the design of the OHTN Cohort Study questionnaire and develop specific questions when necessary
The Priority Population Working groups are comprised of individuals with different lived experience and different technical backgrounds. Contact the Study Coordinator Eliot Winkler at [email protected] if interested in joining one of the working groups, or complete the form below.
Tell us what you think
For study inquiries or any other questions, please contact [email protected], or fill out the form below.
The Ontario HIV Treatment Network Cohort Study (OCS) is a community-governed, province-wide research study aimed at improving the health and well-being of Ontarians living with HIV. Established in 1996, over 3,700 individuals actively participate at nine HIV clinics across the province. The OCS is the largest HIV cohort in Ontario and one of the largest in North America. It represents a diverse group of Ontarians living with HIV, including men and women of different ages, sexual orientations and ethnicities.
The OCS promotes clinical, psychosocial and socio-behavioural research to inform government policy, clinical practice and other care and support services. OCS team members work with leaders in the fields of HIV/AIDS, hepatitis C and other sexually transmitted and bloodborne infections.
A 2015 study assessing engagement in care among OCS participants between 2001 and 2011 found that 87% of participants were receiving regular viral load and CD4 tests; 77% were taking antiretroviral medication; and 76% had a suppressed viral load.